An exploratory, randomized, double blind, placebo controlled, parallel groups Phase II clinical trial to evaluate the efficacy and safety of E-52862 (400 mg) by oral route, in patients with postherpetic neuralgia (PHN).

Trial Profile

An exploratory, randomized, double blind, placebo controlled, parallel groups Phase II clinical trial to evaluate the efficacy and safety of E-52862 (400 mg) by oral route, in patients with postherpetic neuralgia (PHN).

Discontinued
Phase of Trial: Phase II

Latest Information Update: 23 May 2014

At a glance

  • Drugs E 52862 (Primary)
  • Indications Postherpetic neuralgia
  • Focus Therapeutic Use
  • Sponsors Laboratorios Dr. Esteve
  • Most Recent Events

    • 26 Mar 2014 Trial status changed to discontinued as reported by European Clinical Trials Database.
    • 27 Aug 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top